SLC5A2 and type 2 diabetes mellitus: Similarly, a post hoc analyses using modelled estimates of effect, demonstrated the potential additive effects of combination therapy of SGLT2 inhibition, GLP‐1 receptor agonism, and nsMRA with RAS inhibition in a person with type 2 diabetes and albuminuria, compared to conventional care (RAS inhibition alone).